Literature DB >> 26583617

Early Cardiac Involvement and Risk Factors for the Development of Arrhythmia in Patients With β-Thalassemia Major.

Ahmad A Hamed1, Waleed Elguindy, Yasmine I Elhenawy, Rasha H Ibrahim.   

Abstract

BACKGROUND: Cardiac iron overload is the most serious complication in thalassemia; even patients treated with intensive chelation suffer at a certain point from cardiomyopathy and arrhythmia. AIM: The aim of the study was to identify indicators of cardiac dysfunction in thalassemia as well as risk factors associated with the development of arrhythmia. PATIENTS AND METHODS: A total of 45 patients with β-thalassemia major were enrolled in this cross-sectional study. Patients were divided into 2 groups according to the absence (group A) or the presence of arrhythmia (group B). Cardiac parameters in thalassemic groups were evaluated using 24-Holter recording, Stress electrocardiogram, and M-mode echocardiography. Serum ferritin and Cardiac T2* were used to assess the iron status.
RESULTS: Group B showed significantly higher values of cardiac T2* and serum ferritin (P<0.05). Group B patients had significantly higher maximum heart rate with significant attacks of bradycardia and ST segment changes. In addition, they achieved a lower percentage of maximum age predicted heart rate and lower values of maximum metabolic equivalents (P<0.05). Significantly higher values of the left atrial diameter, the interventricular septum diameter, and the left-ventricle posterior wall diameter (P<0.05) were identified in group B.
CONCLUSIONS: The increase in left atrial diameter, interventricular septum diameter, and left-ventricle posterior wall diameter seems to be related to the development of arrhythmia in patients with thalassemia, especially supraventricular arrhythmias.

Entities:  

Mesh:

Year:  2016        PMID: 26583617     DOI: 10.1097/MPH.0000000000000467

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  8 in total

1.  Evaluation of Iron Overload in the Heart and Liver Tissue by Magnetic Resonance Imaging and its Relation to Serum Ferritin and Hepcidin Concentrations in Patients with Thalassemia Syndromes.

Authors:  Volkan Karakus; Ayşegül Kurtoğlu; Dilek Ersil Soysal; Yelda Dere; Selen Bozkurt; Erdal Kurtoğlu
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-07       Impact factor: 0.900

Review 2.  Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update.

Authors:  Richard Gordan; Suwakon Wongjaikam; Judith K Gwathmey; Nipon Chattipakorn; Siriporn C Chattipakorn; Lai-Hua Xie
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

3.  Evaluation of electrocardiography, echocardiography and cardiac T2* for cardiac complications in beta thalassemia major.

Authors:  Fadime Ersoy Dursun; Gönül Açıksarı; Serçin Özkök; Onur İncealtın
Journal:  Int J Cardiovasc Imaging       Date:  2021-10-08       Impact factor: 2.357

4.  Genetic support of a causal relationship between iron status and atrial fibrillation: a Mendelian randomization study.

Authors:  Tianyi Wang; Jun Cheng; Yanggan Wang
Journal:  Genes Nutr       Date:  2022-05-30       Impact factor: 4.423

Review 5.  Iron overload and arrhythmias: Influence of confounding factors.

Authors:  Yukitaka Shizukuda; Douglas R Rosing
Journal:  J Arrhythm       Date:  2019-06-20

6.  Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category?

Authors:  Mehran Karimi; Vincenzo De Sanctis
Journal:  Acta Biomed       Date:  2020-05-11

7.  Heart involvement in transfusion-dependent beta-thalassemia with conventional echocardiography.

Authors:  Hossein Esfahani; Asadolah Tanasan; Mina Rezanejad; Saadat Torabian
Journal:  Caspian J Intern Med       Date:  2021-04

Review 8.  Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers.

Authors:  Vincenzo Russo; Enrico Melillo; Andrea A Papa; Anna Rago; Celeste Chamberland; Gerardo Nigro
Journal:  Cardiol Res Pract       Date:  2019-11-30       Impact factor: 1.866

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.